Search results
Showing 1 to 11 of 11 results for selinexor
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
In development Reference number: GID-TA11201 Expected publication date: 26 February 2026
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Selinexor + pomalidomide + dexamethasone for Multiple myeloma [TSID12333]
Awaiting development Reference number: GID-TA11938 Expected publication date: TBC
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Awaiting development Reference number: GID-TA10694 Expected publication date: TBC
In development Reference number: GID-TA11203 Expected publication date: 08 April 2026
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Awaiting development Reference number: GID-TA11941 Expected publication date: TBC
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.